Clinical Trial Update: Novel CD19/BCMA Dual-Targeted CAR-T Cell Therapy for the Treatment of Relapsed/Refractory Multiple Myeloma [NA]

View source ↗

Summary

A clinical trial is recruiting for a novel CD19/BCMA dual-targeted CAR-T cell therapy for relapsed/refractory multiple myeloma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• CD19/BCMA dual-targeted CAR-T cell therapy

Snippet

Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University | Conditions: Relapse Multiple Myeloma | NA | Status: RECRUITING